The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure. CommentaryDICKSTEIN, Kenneth; MANHENKE, Cord; AARSLAND, Torbjørn et al.International journal of cardiology. 2000, Vol 75, Num 2-3, pp 167-177, issn 0167-5273Article

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatmentVINCENT, Jean-Louis; BERNARD, Gordon R; WONG, Kar et al.Critical care medicine. 2005, Vol 33, Num 10, pp 2266-2277, issn 0090-3493, 12 p.Article

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failureSWEDBERG, Karl; BRISTOW, Michael R; COHN, Jay N et al.Circulation (New York, N.Y.). 2002, Vol 105, Num 15, pp 1797-1803, issn 0009-7322Article

Low levels of protein C are associated With poor outcome in severe sepsisYAN, S. Betty; HELTERBRAND, Jeffrey D; HARTMAN, Daniel L et al.Chest. 2001, Vol 120, Num 3, pp 915-922, issn 0012-3692Article

Extended Evaluation of Recombinant human activated Protein C United States trial (ENHANCE US): A single-arm, phase 3B, multicenter study of Drotrecogin alfa (activated) in Severe SepsisBERNARD, Gordon R; MARGOLIS, Benjamin D; SHANIES, Harvey M et al.Chest. 2004, Vol 125, Num 6, pp 2206-2216, issn 0012-3692, 11 p.Article

Design and methods of the Raloxifene Use for The Heart (RUTH) studyMOSCA, Lori; BARRETT-CONNOR, Elizabeth; ANDERSON, Pamela W et al.The American journal of cardiology. 2001, Vol 88, Num 4, pp 392-395, issn 0002-9149Article

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsisBERNARD, Gordon R; ELY, E. Wesley; HELTERBRAND, Jeffery D et al.Critical care medicine. 2001, Vol 29, Num 11, pp 2051-2059, issn 0090-3493Article